Akari Therapeutics grants director Bazemore restricted stock units in lieu of unpaid cash retainers

Akari Therapeutics granted director Robert B. Bazemore stock options covering 60,000 American Depositary Shares on August 18, 2026. Bazemore also received grants of 13,100 American Depositary Shares on August 18, 2026, and 4,677 on October 5, 2026. The stock options comprise awards covering 45,000 and 15,000 American Depositary Shares, both expiring August 18, 2036. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-047455), on October 16, 2026, and is solely responsible for the information contained therein. (C)